Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accounts Payables (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Accounts Payables for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 4.25% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 4.25% year-over-year, with the annual reading at $1.4 million for FY2025, 4.25% down from the prior year.
  • Accounts Payables hit $1.4 million in Q4 2025 for Bolt Biotherapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.2 million in Q3 2021 to a low of $1.4 million in Q4 2025.
  • Historically, Accounts Payables has averaged $2.7 million across 5 years, with a median of $2.8 million in 2021.
  • Biggest five-year swings in Accounts Payables: skyrocketed 123.65% in 2021 and later plummeted 59.75% in 2024.
  • Year by year, Accounts Payables stood at $3.6 million in 2021, then grew by 0.56% to $3.6 million in 2022, then decreased by 16.89% to $3.0 million in 2023, then plummeted by 49.55% to $1.5 million in 2024, then fell by 4.25% to $1.4 million in 2025.
  • Business Quant data shows Accounts Payables for BOLT at $1.4 million in Q4 2025, $1.5 million in Q3 2025, and $1.9 million in Q2 2025.